Search
Member Login



SCABB WEBINARS (SCABBinars)

 

 

What is a SCABBinar?  

SCABBinar's are one hour webinars that take on cutting edge topics, as well as tried and true topics reinforcing grass roots information at every level. We offer FIVE per year and all are P.A.C.E. and Florida CE Broker approved.

One of the greatest benefits a SCABB membership offers is access to high quality educational programs. SCABBinar's are just one of the ways South Central delivers on that promise.

 


 SCABBinar's are FREE to Members!

SCABB Individual, Physician and Student members receive ALL SCABBinars throughout the year at NO CHARGE.

 

 SCABBinar Schedule

The SCABB Education Committee continues to work hard on the 2023 Education Calendar. As soon as new SCABBinar information is released it will be available here so check back often!

  UPCOMING EVENTS

   -----------------------------------------------------------------------------------------------

November 14, 2024
12:00pm ET | 11:00am CT | 10:00am MT | 9:00am PT

MORE 
Speaker:   Richard Benjamin, MD, PhD, FRCPath
                 Cerus Corporation
                 Chief Medical Officer

Presentation: An Update on Red Cell Pathogen Reduction

Objectives:

  • Describe the process for red cell pathogen reduction and contrast it to platelet pathogen reduction.
  • Discuss the most recent results of the ReCePI clinical trial.

  • List future opportunities for red cell pathogen reduction clinical trials

 Description:

Red Blood Cell (RBC pathogen reduction with amustaline (S-303) /glutathione (GSH) is in late stage development, funded by a contract with the DHHS,  Biomedical Advanced Research and Development Authority (BARDA). Phase III clinical trials investigating chronic RBC transfusion in thalassemia patients (the  SPARC trial) and acute transfusion in cardiovascular surgery (the ReCePI study) have been completed and a large Phase III safety trial in general transfusion patients (the RedeS study) is underway. This presentation will describe the promising results from these trials and the proposed pathway forward to regulatory approval. A robust system for pathogen reduction of RBCs will complement existing approved processes for platelets, plasma and cryoprecipitate, allowing broad spectrum pathogen reduction as an additional safety measure for all transfused blood products.

 

REGISTER NOW

 

 

  

 

 

 

 

PAST EVENTS

----------------------------------------------------------------------------------------------- 

April 25, 2024
 
12:00pm ET | 11:00am CT | 10February 8, 2024
12:00pm ET | 11:00am CT | 10:00am MT | 9:00am PT

Speaker:   Jose F. Quesada MS, MLS(ASCP)CMSBB
                 South Texas Blood & Tissue
                 Sr. Director Manufacturing, Transfusion Services, and IRL

Presentation: Overcoming the Challenge of Platelet Shortages

Objectives:

  • Provide the background on our donor population.
  • Review the strategies developed to overcome the platelet shortage.
  • Discussed the production of cold stored platelets and pool platelets.

 Description:

We have been experiencing a decline in our donor population over the last few years as well as an increase in the demand for products. I will present some data to show our stats for South Texas Blood and Tissue. To support the increased demand, strategies were developed to ensure the Health Care Providers and patients have the necessary blood products to manage their needs. We validated a couple of products: the cold stored platelets and the pool platelets to help with the increase demand.

Share this event with friends and colleagues by clicking below to download the flyer!

February 8 ET | 11:0am CT
MORE INFORMATION

 

REGISTER NOW

 

 

 

 

December 7, 2023
12:00pm ET | 11:00am CT | 10:00am MT | 9:00am PT

 

Speaker: Margaret Keller, PhD
               Executive, National Laboratories
               Senior Director, American Rare Donor Program 

Presentation: The McLeod Phenotype & Other Rare Antigens 

Objectives: 

  • Describe the McLeod phenotype and understand what genome variants are associated with the phenotype and what other conditions can be coinherited.
  • Understand Kx blood group system, its relationship with the Kell blood group system and the alloimmunization risk in patients with the McLeod phenotype.
  • Use Case studies to discuss the complexity of transfusion management of patients with McLeod phenotype. 

Description:
The McLeod phenotype results from inactivation or deletion of the XK gene and a XK: -1 red cell phenotype. It is associated with reduced expression of Kell blood group system antigens. Depending on the genomic variant, patients with McLeod may have additional genetic disorders. We will review the KX blood group system and the XK alleles that have been reported, as well as the risk of alloimmunization. Cases will be used to illustrate the complexity and challenges with transfusion management in these patients. 

Share this event with friends and colleagues by clicking below to download the flyer!

 

DOWNLOAD & SHARE FLYER


  -----------------------------------------------------------------------------------------------

October 26, 2023
12:00pm ET | 11:00am CT | 10:00am MT | 9:00am PT

Speaker: Richard Gammon, MD
               Medical Director, OneBlood

Presentation: Directed Donations and COVID-Vaccinated Blood Donors

Objectives:

  • Describe logistical challenges and risks associated with directed donations.
  • Determine how healthcare providers should respond to patients requesting blood from unvaccinated donors.
  • Evaluate if hospitals should be legally required to provide directed donations, charge extra fees, and be able to allow the unit, if unused, to be placed in the general inventory.

Description:
Hospitals and blood centers have been confronted with many directed donation requests from individuals asking for blood components from COVID-19 unvaccinated blood donors. Blood donors who have received the SARS-CoV-2 mRNA vaccine do not pose a risk to the safety of the blood supply. Information on COVID-19 vaccination or the type of vaccine used is not collected during the donor interview because it is not medically relevant. Hence, it is not possible to label or segregate blood accordingly. While not medically indicated, providing directed donations from COVID-19 unvaccinated donors is also logistically arduous and costly for blood centers and hospitals alike. Healthcare providers should strongly discourage legislation that requires collection facilities to provide a medically unjustified service.

MORE INFORMATION 


-----------------------------------------------------------------------------------------------

July 24, 2023
1:00pm ET | 12:00pm CT | 11:00am MT | 10:00am PT

 Abstract Title: Testing Allogeneic Blood Donors with Unexpected Antibodies for Improved Utilization of Red Blood Cell Inventory

Author: D. Zeman, MLS(ASCP)SBB / 2023 Sol Haberman Winner

-----------------------------------------------------------
Abstract Title: Implementation of a Molecular Genotyping Protocol for Patients with Warm Autoantibodies
Authors: Dorothy Blake1, William S Crews Jr.1, Sandy Wortman1, Laurie Sutor1,2, LeeAnn Walker3, Sarah Burnett-Greenup3
1. Carter BloodCare, Bedford, TX 2. University of Texas Southwestern Medical Center in Dallas, TX
3. University of Texas Medical Branch, Galveston, TX

-----------------------------------------------------------
Abstract Title: Aliquoting Cryoperserved Red Cell Units
Author: Dave Sawh, OneBlood Inc.

-----------------------------------------------------------
Abstract Title: The Science...or Not Behind Deferrals of Blood Donors With a History of Cancer
Authors: Richard R. Gammon1,8 Courtney Hopkins2,8 Gagan Mathur3,8 Susan N. Rossmann4,8 Merlyn Sayers5,6,8 Todd Straus7,8

1. OneBlood, Scientific, Medical, Technical Direction, Orlando, Florida 2. Vitalant, Corporate Medical Affairs, Charleston, South Carolina 3. University of California Irvine, Orange, CA 4. Gulf Coast Regional Blood Center, Houston, Texas 5. Carter Blood Care, Bedford, Texas 6. University of Texas Southwestern Medical Center, Dallas, Texas 7. The Community Blood Center, Appleton, Wisconsin 8. Donor Cancer Deferral Workgroup, America's Blood Centers, Washington, D.C.

-----------------------------------------------------------
Abstract Title: Cost Effectiveness of Allogeneic Adsorption versus Soluble Recombinant Blood Group Protein
Authors: Katherine Dovydaitis BB(ASCP)CM, Tara Francis SBB(ASCP)CM, Cody Riebel BB(ASCP)CM, Michael Gannett MLS(ASCP)SBBCM, Richard Gammon, MD,  OneBlood Inc.

-----------------------------------------------------------
Abstract Title: Improving Team Member Engagement and Process Improvement Using Employee-led Performance Improvement Committee (EPIC)
Author: Mingmar Sherpa, MLS, SBB, DCLS

 
ABSTRACT JOURNAL
A